Experience with regorafenib in the treatment of hepatocellular carcinoma

Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Granito, Alessandro, Forgione, Antonella, Marinelli, Sara, Renzulli, Matteo, Ielasi, Luca, Sansone, Vito, Benevento, Francesca, Piscaglia, Fabio, Tovoli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165525/
https://www.ncbi.nlm.nih.gov/pubmed/34104211
http://dx.doi.org/10.1177/17562848211016959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165525/
https://www.ncbi.nlm.nih.gov/pubmed/34104211
http://dx.doi.org/10.1177/17562848211016959

Ejemplares similares